TB-500 5mg

TB-500 is a research-material name associated with thymosin beta-4 fragment literature [3] . Research buyers can evaluate compound identity, COA data, analytical testing, lot traceability, and label consistency before laboratory procurement. Published studies provide scientific background, not verification of a supplier’s lot.

• TB-500 should be evaluated through compound identity documentation, not name recognition alone, because published analytical literature has identified TB-500 in relation to an N-acetylated thymosin beta-4 17–23 fragment [3].
• Thymosin beta-4 is encoded by the TMSB4X gene, which NCBI describes as an actin-sequestering protein involved in actin polymerization, cell proliferation, migration, and differentiation [1].
• UniProt lists human thymosin beta-4 under TMSB4X and describes actin-monomer binding as a core functional annotation [2].
• Research literature examines actin binding, cell migration, angiogenesis, Akt, cytokines, and cell signaling under specific experimental conditions. These findings do not establish effects of a supplier’s product [4] [7] [8] .
• Documentation review should prioritize a batch-specific certificate of analysis, HPLC purity data, LC-MS or comparable identity support, COA date, lot number, and supplier documentation [12] [13].
• Research procurement should compare the product label, COA, COA library entry, analytical report, storage record, and batch documentation before any laboratory purchasing decision.

Buy TB-500 for Research: What Should Researchers Check First?

Researchers looking to buy TB-500 for research should first check whether the product page provides clear RUO labeling, batch-specific COA documentation, peptide identity support, and analytical testing information. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. The safer buying framework is documentation-first, not claim-first.

What Should Researchers Check Before Buying TB-500?

TB-500 is offered for laboratory research only. Review the compound identity and batch-specific documentation before procurement.

Analytical literature has described TB-500 using high-performance liquid chromatography and high-resolution mass spectrometry to identify an N-acetylated thymosin beta-4 fragment [3]. Synthetic peptide quality studies also show that peptide materials can contain structure-related impurities, making documentation review part of technical procurement [18].

What Documentation Should Come Before Procurement Review?

Before procurement review, researchers should look for the compound name, lot number, batch-specific COA, analytical method, purity record, and identity-supporting test data. These documents should tell the same story.

A COA should be treated as a batch record, not a generic marketing asset. FDA’s Q2(R2) guidance frames analytical validation around measurements such as identity, purity, impurities, and quantitative or qualitative measurements, which makes method clarity important when reviewing testing records [12].

Why Does Research-Use-Only Labeling Matter?

RUO labeling identifies the material as intended for laboratory research rather than consumer use. FDA guidance for RUO-labeled in vitro diagnostic products discusses consistency between labeling and intended research use [11] . That IVD guidance does not establish regulated status for a research peptide.

Research-Use-Only TB-500 Materials

Which lot does the COA cover? Which test methods support identity and purity? Where can the batch record be reviewed?

RUO Meaning for Peptide Research Materials

RUO means the material is intended for laboratory research only.

What Is TB-500 in Peptide Research Literature?

TB-500 is commonly discussed in research-material contexts as a synthetic peptide associated with a thymosin beta-4 fragment. In one analytical characterization study, researchers described detection and identification of the N-acetylated 17–23 fragment of human thymosin beta-4, Ac-LKKTETQ, in TB-500 using HPLC and high-resolution mass spectrometry [3].

Compound Identity and Peptide Info Consistency

Compound identity should be verified by sequence documentation, molecular record, and analytical data.

NCBI identifies TMSB4X as the gene for thymosin beta 4 X-linked and describes the encoded protein as involved in actin polymerization, proliferation, migration, and differentiation [1]. UniProt’s thymosin beta-4 entry also supports actin-monomer binding as a core annotation [2].

TB500 Relationship to Thymosin Beta-4 Fragment Research

The compact spelling TB500, the hyphenated TB-500, and the spaced form TB 500 should be treated as naming variants that require documentation alignment.

TB-500 Identity and Related Research

TB-500 identity review draws on fragment-specific analytical literature. Related thymosin beta-4 studies examine actin binding and cell migration, but full-length protein and fragment findings require separate interpretation.

Thymosin Beta and Thymosin Beta 4 Naming Variants

Thymosin beta, thymosin beta 4, thymosin beta-4, and Tβ4 can appear in scientific literature. Researchers should treat these as naming signals that need source review, because database entries, full-length protein discussions, and fragment-specific papers may not refer to identical materials.

Mutational analysis literature mapped actin-binding regions of thymosin beta-4 using synthesized variants, showing why sequence-level detail matters in this peptide family [4]. Structural studies also describe how thymosin beta-4 interacts with actin, which adds context for why actin-binding appears often in the research literature [5].

Where Does BPC-157 Fit as a Documentation Reference?

BPC-157 may appear near TB-500 in supplier catalogs because both are often discussed within broad cellular pathway research categories. That does not make them interchangeable.

For product-page review, the better comparison is documentation quality. Researchers can compare whether each listing provides a COA, lot number, purity method, identity method, storage notation, and clear RUO labeling.

Scientific Background for Synthetic Thymosin Research

Synthetic thymosin research examines peptide identity, actin interactions, and cellular models. These studies provide scientific context, not verification of a catalog product.

Synthetic Peptide Characterization

Synthetic peptide context starts with the molecule itself. In the TB-500 literature, an N-acetylated thymosin beta-4 fragment was characterized with HPLC and high-resolution mass spectrometry [3].

Mass spectrometry is well suited to synthetic peptide identity and purity analysis because the expected sequence is known and the analysis can compare observed mass data with the expected molecule [15]. This supports documentation review without making a claim about product performance.

Published Models and Cellular Pathway Interest

Published models have examined thymosin beta-4 in relation to actin, cell migration, endothelial cell behavior, angiogenesis, and signaling pathway activity [7] [8]. Review literature also describes Tβ4 in multiple signaling contexts, including cytokine-related and cell migration pathways [10].

The important research boundary is that model-specific literature does not become a statement about a product. It remains scientific context for qualified researchers reviewing a research material.

What Can Literature Support Without Overstatement?

Literature can establish that researchers examined a pathway, peptide family, or experimental model. It does not verify the identity, purity, or performance of a particular supplied lot.

Actin-binding literature helps explain thymosin beta-4’s role in cellular models [4] [5] . It does not establish that a supplier’s product produces the same biological observations.

Mechanism of Action Context in Published Research

Mechanistic studies need interpretation according to the exact peptide, model, and experimental conditions investigated.

Actin-Binding, Cell Migration, and Angiogenesis Models

Thymosin beta-4 is widely discussed as an actin-binding peptide. Structural work has shown thymosin beta-4 interaction with actin monomers, and later structural work described thymosin beta-4/profilin exchange in relation to actin filament polymerization [5] [6].

Experimental literature has also examined the actin-binding site in relation to endothelial cell migration and angiogenesis models [7].

Akt, Cytokines, and Cell Signaling in Research

Akt and cell signaling appear in thymosin beta-4 literature because some studies have examined integrin-linked kinase and Akt/PKB-associated pathways in preclinical and cellular models [8]. Developmental cell literature has also described coordination between actin polymerization and ILK–Akt2 activity during endothelial cell migration [9].

Cytokine-related discussion appears in review literature as part of broader Tβ4 signaling context [10].

How Should Researchers Interpret TB-500 Research?

Researchers should interpret TB-500 research by separating compound identity, model type, evidence level, and RUO procurement relevance.

Why Is Pathway Relevance Not a Product Claim?

Pathway relevance means that a molecule, peptide family, or fragment appears in a research model. It does not establish that the same observations apply to other materials or settings.

This distinction is especially important for TB-500 because the broader thymosin beta-4 literature includes full-length protein studies, fragment studies, and pathway reviews [3] [10]. Product documentation should focus on the specific research material and the batch record.

What Does Preclinical Literature Add to Evidence Review?

Preclinical literature adds mechanistic context, model diversity, and source-quality signals. It does not provide product-use guidance for RUO materials.

How Do Source Quality Filters Reduce Overstatement?

Evaluate the source type and the question it answers. Database records, analytical characterization papers, structural biology studies, and method guidance provide different kinds of evidence relevant to TB-500 review.

Identify the source type, determine whether its findings concern a full-length protein, fragment, or experimental model, and check whether they apply to the material under evaluation.

How Should Research Literature Stay Separate From Product Claims?

Research literature should stay separate from product claims by preserving the context of each study. Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials.

Why Should Study Findings Stay Separate From Product Positioning?

Study findings often depend on model conditions, assay design, and the exact material tested.

Reported effects depend on the study model and the exact material tested. They cannot be assumed to apply to a different preparation or setting.

What Documentation Supports RUO Procurement?

For TB-500, review compound name, sequence information when available, COA data, HPLC, LC-MS, lot number, and storage records.

Published literature provides scientific context; lot-specific analytical documentation provides separate evidence about the supplied batch.

Certificate of Analysis Review for TB-500

A certificate of analysis is one of the most important documents on a TB-500 product page. It should help researchers connect the product listing to a specific lot and analytical record.

What COA Fields Should Researchers Compare?

Researchers should compare the compound name, lot number, test date, purity value, analytical method, identity-supporting method, reporting lab, and any notes linked to the batch. FDA Q2(R2) discusses validation concepts for analytical procedures, including identity, purity, impurities, and qualitative or quantitative measurements [12].

For peptide reference materials, USP-affiliated literature describes analytical strategies that can include RP-HPLC and other testing to support peptide quality documentation [14]. This makes method visibility important when reviewing a COA.

How Does the COA Library Support Batch Review?

A COA library supports batch review by making batch-specific documentation easier to locate and compare. The key is matching the COA to the lot shown on the product listing.

A COA library should not be treated as a broad purity promise. It is a document access point that supports lot-level review.

Peptide Purity and Identity Testing Considerations

Peptide purity and peptide identity are related but different. A purity result describes a chromatographic or analytical finding, while identity testing asks whether the intended molecule is supported by the data.

How Does HPLC Support Peptide Purity Review?

HPLC supports peptide purity review by separating peptide-related components under defined chromatographic conditions. Peptide HPLC literature describes modes such as reversed-phase, ion-exchange, and size-exclusion chromatography for peptide analysis and purification contexts [16].

For a TB-500 product page, HPLC is most useful when the COA reports the method, chromatogram context, and lot connection. A purity number without method context is less useful for documentation review.

How Does LC-MS Support Identity Verification?

LC-MS supports identity verification by combining liquid chromatography with mass spectrometric data. Synthetic peptide mass spectrometry methods can compare observed mass information to the expected synthetic peptide sequence [15].

For TB-500, LC-MS or high-resolution MS is especially relevant because the analytical literature identifying the N-acetylated thymosin beta-4 fragment relied on HPLC and HRMS [3]. This supports identity review without implying any product claim.

Analytical Verification Workflow for TB-500 Research Materials

Analytical verification should work like a documentation workflow. The goal is to compare the product listing, COA, analytical data, and batch details.

What Does Mass Spectrometry Add to Compound Confirmation?

Mass spectrometry adds molecular confirmation by measuring mass-related signals that can be compared with expected peptide identity. In synthetic peptide analysis, MS is widely used to support identity and purity review [15].

Research verification workflow:

1. Verify that the compound name, synonym, and lot number match across the product listing and documentation.
2. Review the batch-specific certificate of analysis.
3. Check whether the purity testing method is listed.
4. Confirm whether identity testing is supported by LC-MS, HRMS, or another suitable analytical method.
5. Review chromatogram or mass data when available.
6. Check the COA date and lab source.
7. Document storage and handling conditions in the laboratory record.

Lot Traceability and Batch-Specific Documentation

Lot traceability connects a research material to a specific production and testing record. For peptide procurement, that connection is central to documentation quality.

Why Do Lot Numbers Matter in Research Procurement?

Lot numbers matter because every batch may have its own analytical record. Without lot matching, a COA cannot be confidently tied to the material under review.

Batch-specific documentation also supports reproducibility in laboratory records. For peptide materials, procurement teams should record the lot number, COA date, label details, and storage notes.

How Does Third-Party Testing Support Documentation Review?

Third-party tested documentation can add confidence when the reporting lab, method, and batch match are clear. It should still be reviewed as documentation, not as a marketing statement.

The useful question is not whether a badge appears on the page. The useful question is whether the third-party testing record identifies the peptide, the lot, the method, and the date.

Supplier, Labeling, and Storage Documentation Review

Supplier review should connect the product page to the full documentation set. For TB-500, that means label clarity, RUO language, COA access, purity method, identity method, lot traceability, and storage documentation.

Lyophilized Powder Form and Labeling Consistency

When a listing states that the research material is supplied in lyophilized powder form, that statement should match the label and supplier documentation. The powder form should be handled as a catalog and documentation detail.

Peptide literature on reference standards and laboratory assay materials emphasizes the importance of characterization, storage, and handling records for peptide materials used in mass spectrometry-based assays [17]. For product-page review, the key point is record consistency.

Solubility Notes as Research Documentation

Solubility notes belong in research documentation because they describe solution chemistry considerations. They should not replace identity testing, purity review, or batch-specific COA review.

Supplier Records Research Buyers Should Compare

Research buyers should compare the product listing, COA, COA library entry, label text, batch number, analytical test summary, storage notes, and supplier documentation. A strong record set is internally consistent.

Quality and documentation checklist:

• Verify that the compound is labeled for research use only.
• Review the batch-specific certificate of analysis.
• Confirm that purity data are supported by analytical testing.
• Check that the lot number on the COA matches the product documentation.
• Compare compound name, molecular record, and sequence information when available.
• Assess whether the product page avoids consumer-facing or clinical-use positioning.
• Document storage and handling conditions in a laboratory record.

Research Procurement Checklist Before Teams Buy TB-500 for Research

Research procurement should end with documentation review, not a claim review. For TB-500, the strongest procurement path is label → COA → identity method → purity method → lot match → supplier record → RUO review.

How Does Documentation Support TB-500 Procurement?

Documentation gives lab teams a consistent record to evaluate before supplier selection.

For synthetic peptides, literature on quality evaluation shows why identity and impurity review matter; peptide-related impurities can be present and may require analytical methods to identify or characterize them [18]. That makes documentation clarity part of responsible procurement.

What Final Records Should Lab Teams Review?

Final records should include the product listing, label, batch-specific COA, HPLC record, LC-MS or comparable identity support, COA library entry, lot number, test date, supplier documentation, and storage notes. The final review should also confirm that RUO boundaries remain clear.

Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.

Review the product-page documentation, COA details, and RUO labeling before evaluating this compound for laboratory research.

FAQs

What is TB500 peptide in research literature?

TB500 is a naming variant for TB-500 in research-material records. Analytical work identified an N-acetylated thymosin beta-4 17–23 fragment using HPLC and high-resolution mass spectrometry [3] .

What should researchers consider before they buy TB-500 for research?

Researchers should consider documentation before they buy TB-500 for research. A research-focused review should check RUO labeling, compound name consistency, batch-specific COA data, lot traceability, HPLC purity information, LC-MS or comparable identity support, and supplier documentation. The commercial question is safest when it remains tied to laboratory procurement and product records.

How does TB-500 relate to protein thymosin beta-4?

TB-500 relates to protein thymosin beta-4 through fragment-focused research language. NCBI describes thymosin beta-4 as an actin-associated protein involved in actin polymerization, cell proliferation, migration, and differentiation [1]. UniProt also lists actin-monomer binding for the human thymosin beta-4 protein entry [2]. These database records support literature context, not product claims.

What Do Akt/PKB Studies Add to the Research Context?

Thymosin beta-4 literature includes studies of Protein kinase B and Akt/PKB-associated cell signaling models [8] [9] . Findings depend on the peptide and experimental system investigated.

Why do researchers review COA documentation for TB-500?

Researchers review COA documentation for TB-500 because it connects a product listing to a batch-specific record. A useful COA review checks the compound name, lot number, test date, purity method, and identity-supporting method. COA review works best when paired with analytical testing records and consistent supplier documentation.

How should published literature be interpreted for TB-500 research materials?

Interpret TB-500-related literature according to the exact peptide, model, and methods studied. Observations about pathway activity, migration, or differentiation do not establish the performance of a catalog product or replace identity testing, COA review, and lot traceability.

---

Researchers Cited in This Guide

The researchers listed below are cited for relevant published work. Their inclusion does not imply that they wrote, reviewed, or endorsed this guide or Pure Lab Peptides products.

Peter Van Eenoo

Author profile: Ghent University Academic Bibliography

Peter Van Eenoo’s publications examine peptide characterization using LC-MS and high-resolution mass spectrometry. His analytical work provides background for evaluating peptide identity and the methods supporting it.

Selected publications:

• Analytical characterization of a thymosin beta-4 fragment identified in TB-500 — Drug Testing and Analysis, 2012. DOI: 10.1002/dta.1402
• A review of LC-MS-based analytical approaches for small peptide research materials — Journal of Chromatography B, 2021. DOI: 10.1016/j.jchromb.2021.122551

Robert C. Robinson

Author profile: VISTEC Faculty Profile

Robert C. Robinson’s structural biology publications examine thymosin beta-4 interactions with actin and the relationship between profilin exchange and actin filament polymerization. This work provides mechanistic background for interpreting thymosin beta-4 research.

Selected publications:

• Structural basis of actin sequestration by thymosin-β4 — The EMBO Journal, 2004. DOI: 10.1038/sj.emboj.7600372
• Structural basis of thymosin-β4/profilin exchange leading to actin filament polymerization — Proceedings of the National Academy of Sciences, 2014. DOI: 10.1073/pnas.1412271111

REFERENCES

1. NCBI. TMSB4X thymosin beta 4 X-linked gene record. National Center for Biotechnology Information. Updated 2026.
2. UniProt Consortium. Thymosin beta-4, human TMSB4X protein entry. UniProtKB/Swiss-Prot. Accessed 2026.
3. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. TB-500 analytical characterization study. Drug Testing and Analysis. 2012;4(9):733–738. DOI: 10.1002/dta.1402.
4. Van Troys M, Dewitte D, Goethals M, Carlier MF, Vandekerckhove J, Ampe C. The actin binding site of thymosin beta 4 mapped by mutational analysis. The EMBO Journal. 1996;15(2):201–210. PMID: 8617195.
5. Irobi E, Aguda AH, Larsson M, Guerin C, Yin HL, Burtnick LD, Blanchoin L, Robinson RC. Structural basis of actin sequestration by thymosin-β4. The EMBO Journal. 2004;23(18):3599–3608. DOI: 10.1038/sj.emboj.7600372.
6. Xue B, Leyrat C, Grimes JM, Robinson RC. Structural basis of thymosin-β4/profilin exchange leading to actin filament polymerization. Proceedings of the National Academy of Sciences. 2014;111(43):E4596–E4605. DOI: 10.1073/pnas.1412271111.
7. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. Actin-binding site and angiogenesis study for thymosin β4. The FASEB Journal. 2003;17(14):2103–2105. DOI: 10.1096/fj.03-0121fje.
8. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta-4 ILK/Akt signaling study. Nature. 2004;432(7016):466–472. DOI: 10.1038/nature03000. PMID: 15565145.
9. Fan Y, Gong Y, Ghosh PK, Graham LM, Fox PL. Spatial coordination of actin polymerization and ILK–Akt2 activity during endothelial cell migration. Developmental Cell. 2009;16(5):661–674. DOI: 10.1016/j.devcel.2009.03.009.
10. Xing Y, Ye Y, Zuo H, et al. Progress on the function and application of thymosin β4. Frontiers in Endocrinology. 2021;12:767785. DOI: 10.3389/fendo.2021.767785.
11. U.S. Food and Drug Administration. Distribution of products labeled for research use only or investigational use only. FDA Guidance for Industry and FDA Staff. 2013; content current 2018.
12. U.S. Food and Drug Administration. Q2(R2) Validation of Analytical Procedures. FDA/ICH Guidance. March 2024.
13. U.S. Food and Drug Administration. Q14 Analytical Procedure Development. FDA/ICH Guidance. March 2024.
14. McCarthy D, Szajek AY, Snyder R, et al. USP reference standard strategy for synthetic peptides. AAPS Journal. 2023. PMID: 36949371.
15. Prabhala BK, et al. Characterization of synthetic peptides by mass spectrometry. Methods in Molecular Biology. 2015. PMID: 26424265.
16. Mant CT, Chen Y, Hodges RS. HPLC analysis and purification of peptides. Methods in Molecular Biology. 2007;386:3–55.
17. Hoofnagle AN, Whiteaker JR, Carr SA, et al. Recommendations for generation, quantification, storage, and handling of peptides used for mass spectrometry-based assays. Clinical Chemistry. 2016;62(1):48–69. DOI: 10.1373/clinchem.2015.250563.
18. Verbeke F, De Craemer S, Debunne N, et al. Quality evaluation of synthetic quorum sensing peptides used in research. PLOS ONE. 2015;10(7):e0133376. DOI: 10.1371/journal.pone.0133376.

---

Research Disclaimer

This material is supplied strictly for in vitro laboratory research and is not for human or veterinary use. Published studies describe specific experimental materials, models, and methods; they do not establish the safety, efficacy, or suitability of this catalog product for non-research use. Review the original publications and the lot-specific analytical documentation independently.